THEORY AND METHODS

An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas

J Marrugat, R D'Agostino, L Sullivan, R Elosua, P Wilson, J Ordovas, P Solanas, F Cerdón, R Ramos, J Sala, R Masiá, W B Kannel

J Epidemiol Community Health 2003;**57**:634–638

See end of article for authors' affiliations

Correspondence to:
Dr J Marrugat, Unitat de
Lípids i Epidemiologia
Cardiovascular, Institut
Municipal d'Investigació
Mèdica (IMIM), Carrer Dr.
Aiguader, 80, E-08003
Barcelona, Spain;
jmarrugat@imim.es

Accepted for publication
26 December 2002

Aim: To determine whether the Framingham function accurately predicts the 10 year risk of coronary disease and to adapt this predictive method to the characteristics of a Spanish population.

Method and Results: A Framingham function for predicting 10 year coronary deaths and non-fatal myocardial infarction was applied to the population of the province of Gerona, Spain, where the cumulated incidence rate of myocardial infarction has been determined since 1988 by a specific registry. The prevalence of cardiovascular risk factors in this region of Spain was established in 1995 by a cross sectional study on a representative sample of 1748 people. The number of cases estimated by the Framingham function for 10 year coronary deaths and non-fatal myocardial infarction was compared with that observed. The Framingham function estimated 2425 coronary heart disease cases in women and 1181 were observed. In men, 9919 were estimated and 3706 were observed. Recalibrating the Framingham equations to the event rate and the prevalence of the risk factors in Gerona led to estimates very close to the number of cases observed in Gerona men and women.

Conclusions: The Framingham function estimates more than doubled the actual risk of coronary disease observed in north east Spain. After calibration, the Framingham function became an effective method of estimating the risk in this region with low coronary heart disease incidence.

The incidence rate of myocardial infarction (MI) in Spain and other southern European countries is unexpectedly low given the high prevalence of cardiovascular risk factors.^{1–4} Nevertheless, this disease continues to be the leading cause of death in Spanish men and the third in women.⁵ The reasons for this paradox remain unclear. It has been hypothesised that regional factors may confer protection.^{6–7} Therefore, individual cardiovascular risk estimates provided by the functions based on classic risk factor prevalence and event rates used in the Framingham charts may overestimate the actual individual risk in Spanish subjects.^{6–10}

The Seven Countries study has demonstrated that the southern Europe cohort presented a lower risk of fatal coronary heart disease (CHD) over 25 years than other European or USA cohorts.^{11–12} However, no quantitative estimates are available to adjust the results of CHD risk estimation to southern European populations. Regions such as the province of Gerona, Spain, in which MI incidence and attack rates have been monitored over a long period, provide an appropriate setting for assessing the utility of the Framingham function applied to southern European populations.

This study examines the accuracy of the Framingham function in predicting the 10 year coronary events rate in Gerona, a Mediterranean area with a low MI incidence rate, and adapts this predictive instrument for use in Spain.

METHODS

Since 1988, the REGICOR (Registre Gironí del Cor) MI population registry has been operating in Gerona, in the north east of Spain. The 1991 census recorded 280 865 residents aged 25 to 74 in the area. Medical facilities include one coronary care unit and seven local hospitals. Residents in the study area with suspected non-fatal MI or coronary deaths were investigated, and after 1996 those over 74 were also included.

Case finding included prospectively registering MI patients admitted to the only coronary care unit in the region, and

screening discharge records of patients admitted to all hospitals and clinics in the area or referred outside the geographical area. Medical records of patients with death certificates containing 410–414 International Classification of Diseases 9th revision codes were reviewed to identify coronary deaths not detected by the other case finding procedures. Physicians who signed the death certificate, relatives of the deceased, and witnesses at the time of death were interviewed as necessary to complete the information on a case.

Each case was classified according to the MONICA algorithm.¹³ Type of symptoms, electrocardiographic findings, and cardiac enzyme values determined the diagnosis of non-fatal MI. These criteria and history of CHD and necropsy findings in coronary deaths yielded the following diagnostic categories: fatal and non-fatal definite, and fatal possible or insufficient data cases.

A cross sectional survey was conducted on 1748 participants (72% response rate) aged 25 to 74 randomly selected from the population of Gerona, Spain in 1995. All established major cardiovascular risk factors were measured by standard methods.⁴

Participants were considered to be diabetic if they had been diagnosed with diabetes, were following a diabetic diet, or taking medications such as oral agents or insulin. Persons with a fasting glucose level >139 mg/dl were also considered diabetic. Participants were considered smokers when they reported smoking ≥1 cigarette per day, and hypertensive if they were taking anti-hypertensive therapy or had a blood pressure ≥140/90 mmHg.

Sex by age (10 year groups) subgroups were established in the whole population based on the distribution observed in the random sample. Only subjects aged 35 to 74 were considered in this study.

The Framingham function to assess the 10 year risk of coronary death or non-fatal MI (hard CHD) event in initially

Abbreviations: MI, myocardial infarction; CHD, coronary heart disease

Table 1 Cox regression coefficients and 95% confidence intervals (95% CI) for the risk factors included in the Framingham functions for 10 year incidence of coronary deaths and recognised non-fatal myocardial infarction (hard end points) by sex

Risk factors (units)	Risk factor categories	Men Cox regression coefficient estimates (95% CI)	Women Cox regression coefficient estimates (95% CI)
Age (y)	Mean	0.05 (0.04 to 0.07)	0.17 (-0.03 to 0.37)
Age (y) squared	Mean squared	-	-0.001 (0.003 to 0.001)
Total cholesterol (mg/dl)	<160	-0.38 (-1.18 to 0.42)	-0.21 (-1.73 to 1.32)
	160-199	0.00	0.00
	200-239	0.57 (0.22 to 0.92)	0.44 (-0.21 to 1.09)
	240-279	0.74 (0.36 to 1.13)	0.56 (-0.11 to 1.22)
	≥280	0.83 (0.33 to 1.32)	0.89 (0.19 to 1.80)
HDL-cholesterol (mg/dl)	<35	0.61 (0.16 to 1.06)	0.73 (0.00 to 1.46)
	35-44	0.37 (-0.06 to 0.79)	0.60 (0.05 to 1.15)
	45-49	0.00	0.60 (0.05 to 1.14)
	50-59	0.00 (-0.47 to 0.47)	0.00
	>59	-0.46 (-1.09 to 0.17)	-0.54 (-1.10 to 0.02)
Blood pressure (mm Hg)	Optimal (S<120)/(D<80)	0.09 (-0.41 to 0.60)	-0.74 (-1.53 to 0.05)
	Normal (S 120-129)/(D 80-84)	0.00	0.00
	High normal (S 130-139)/(D 85-89)	0.42 (-0.02 to 0.86)	-0.37 (-1.09 to 0.35)
	Stage I (S 140-159)/(D90-99)	0.66 (0.25 to 1.07)	0.22 (-0.38 to 0.81)
	Stage II-IV (S≥160)/(D≥100)	0.90 (0.46 to 1.33)	0.61 (0.00 to 1.21)
Diabetes		0.53 (0.11 to 0.94)	0.87 (0.33 to 1.40)
Smoking	Current 1 cigarette/day consumption	0.73 (0.47 to 0.98)	0.98 (0.57 to 1.38)

S, systolic blood pressure; D, diastolic blood pressure; HDL, high density lipoprotein. *Risk factor means refers to the mean age and to the proportion of population in each level of the risk factors.

cardiovascular disease free subjects¹³ (table 1) was used. This function was based on previously published functions⁸ used in 10 year individual risk charts in the industrialised world¹⁰⁻¹⁷ (see appendix). The classic Framingham function⁸ was not used, as total CHD also includes angina and coronary insufficiency, vascular events not considered in the Gerona registry.

The expected number of 10 year hard CHD events in each sex by age group in the Gerona population was estimated using the means of the risk factors in those groups in the Framingham hard CHD equations, and was compared with the number observed in the MI population registry. The observed number of cases used in the comparisons was derived from the annual MI incidence between 1990 and 1997. MI cumulated incidence was averaged between each age group and the next for each particular 10 year age group to simulate a 10 year follow up.

Statistical analysis

Statistical analysis consisted on description of rates per 100 000 inhabitants. Annual population variation was described by the coefficient of variation (that is, standard deviation to mean ratio). Firstly, the Framingham prediction functions were used with the underlying CHD event rate and the means of the risk factor (that is, the mean age and the proportion of population in each level of the risk factors) observed in Framingham. To calculate the 10 year risk for a particular individual, three elements are necessary: the means of the risk factors and the average 10 year CHD event rate in the target population, and the regression coefficients from the risk function. The recalibration procedure consists of replacing the Framingham means of the risk factors and the average event rate by those of the target population,¹³ under the assumption that the effects of the risk factors are reasonably

Table 2 Population prevalence of each level of the risk factors in Framingham, United States and Gerona, Spain by sex

Risk factors (units)	Risk factor categories	Men		Women	
		Framingham risk factor means* (%)	Gerona risk factor means* (%)	Framingham risk factor means* (%)	Gerona risk factor means* (%)
Age (y)	Mean	48.3	54.6	49.6	54.2
Age (y) squared	Mean squared			2604.5	2931.7
Total cholesterol (mg/dl)	<160	7.5	5.9	7.9	4.9
	160-199				
	200-239	39.0	34.8	32.7	35.3
	240-279	16.5	28.1	20.0	24.6
	≥280	5.7	10.5	9.1	13.4
HDL-cholesterol (mg/dl)	<35	19.2	17.0	4.3	3.8
	35-44	35.7	31.9	14.9	17.0
	45-49			12.4	12.3
	50-59	19.0	20.9		
	>59	10.6	17.5	40.7	40.9
Blood pressure (mm Hg)	Optimal (S<120)/(D<80)	20.2	18.1	34.8	25.5
	Normal (S 120-129)/(D 80-84)				
	High normal (S 130-139)/(D 85-89)	20.2	20.1	15.0	16.2
	Stage I (S 140-159)/(D90-99)	22.5	28.4	18.6	28.6
	Stage III-V (S≥160)/(D≥100)	12.8	14.7	10.0	11.5
Diabetes		5.0	9.3	3.8	6.8
Smoking	Current 1 cigarette/day consumption	40.3	42.3	37.8	12.0
10 year event rate	Coronary deaths and recognised non-fatal myocardial infarction	0.057	0.035	0.012	0.011

Abbreviations as in table 1. *Risk factor means refers to the mean age and to the proportion of population in each level of the risk factors.

Figure 1 Coronary deaths and non-fatal myocardial infarction cumulated incidence in the population aged 35 to 64 in Gerona 1988–97.

universal.^{11 12} (See appendix and table 1). The estimated numbers of events were compared with those observed for men and women. Microsoft Excel and SPSS packages were used for spreadsheet and statistical analysis, respectively.

RESULTS

No statistically significant variation was observed in the MI cumulated incidence rate between 1990 and 1997 in Gerona (fig 1). The average yearly MI attack rate was 349/100 000 men aged 35 to 74 years and 109/100 000 women of the same age

group. The coefficient of variation of the population over the 10 year study period was very low (4.2%). The risk factor prevalence in each sex and age group is shown in table 3.

The estimated number of coronary events by the Framingham function was 2425 in women while that observed was only 1181 (ratio 2.1). In men 9919 events were expected and only 3706 were observed (ratio 2.7). The ratio decreased with age in women, but remained steady in men (table 4).

After calibration adjustment of the Framingham prediction function using the CHD event rates and the means of the risk factors observed in Gerona, the expected figures closely matched the observed number of CHD events in women (1671, ratio 1.4) and men (3880, ratio 1.1). However, as shown in table 4, the estimated to observed ratio still differed from 1.0 in women. In men, the expected numbers were very close to the observed numbers of events.

DISCUSSION

Overestimation of CHD risk by the Framingham function was quantified in Gerona, Spain, where MI rates are low.¹ The overestimation is of an order of magnitude of three in men and two in women aged 35–74. This finding confirms the results of a population study that showed that Framingham function also overestimated the coronary risk in Italy.¹⁸ However, a

Table 3 Risk factor prevalence in population aged 35 to 74 free of coronary heart disease in Gerona (1995)

	35–44 years	45–54 years	55–64 years	65–74 years
Men	n=172	n=175	n=182	n=180
Diabetes	6.1%	13.5%	19.3%	23.3%
Smokers*	41.5%	31.8%	24.5%	18.9%
Hypertension†	16.5%	35.3%	49.5%	69.6%
Systolic blood pressure‡	123 (13)	133 (20)	138 (17)	147 (19)
Diastolic blood pressure‡	77 (10)	82 (12)	81 (10)	81 (10)
Mean total cholesterol§	226 (42)	232 (45)	235 (41)	217 (39)
Mean HDL cholesterol§	48 (15)	47 (14)	49 (14)	47 (13)
Women	n=188	n=200	n=208	n=175
Diabetes	2.8%	7.5%	19.2%	20.6%
Smokers*	31.8%	7.5%	3.7%	1.8%
Hypertension†	7.3%	28.0%	59.0%	76.4%
Systolic blood pressure‡	114 (14)	126 (16)	140 (18)	147 (18)
Diastolic blood pressure‡	69 (10)	75 (11)	81 (10)	81 (10)
Mean total cholesterol§	205 (35)	227 (49)	236 (44)	247 (41)
Mean HDL cholesterol§	56 (14)	60 (15)	55 (14)	58 (15)

*Current smokers of at least one cigarette per day. †Blood pressure higher than or equal to 90/140 mm Hg or treated. ‡Mean (SD) in mm Hg. §Mean (SD) in mg/dl.

Table 4 Observed and expected cases of coronary deaths and non-fatal myocardial infarction in Gerona according to the average actual local myocardial infarction cumulated incidence rate 1990–97 and to the Framingham function, respectively, by age group and sex

	Average population	10 year average incidence rate per 100000*	Observed number of events*	Expected number of events unadjusted†	Unadjusted ratio	Expected number of events adjusted for the Gerona means and CHD event rate‡	Adjusted Ratio
Men							
35–44	33962	109	370	1178	3.2	447	1.2
45–54	26536	263	698	1833	2.6	702	1.0
55–64	24861	475	1181	2935	2.5	1143	1.0
65–74	20848	699	1457	3973	2.7	1588	1.1
Overall	106207		3706	9919	2.7	3880	1.1
Women							
35–44	32594	12	39	150	3.8	103	2.6
45–54	25452	50	127	252	2.0	173	1.4
55–64	26021	135	351	775	2.2	533	1.5
65–74	23871	278	664	1248	1.9	862	1.3
Overall	107938		1181	2425	2.1	1671	1.4

*Calculated combining the average incidence rate corresponding to consecutive sex and age groups. See details in Methods. Ratio, expected to observed ratio. †Calculated using the Framingham risk factor means and 10 year underlying CHD event rate in the Framingham function. ‡Risk factor means and 10 year underlying CHD event rate of Gerona used in the Framingham function. Risk factor means refers to mean age and the proportion of population in each level of the risk factors.

comparatively simple calibration procedure provides more accurate estimates of the individual MI risk with the Framingham function in our region.

In Spain, the prevalence of cardiovascular risk factors is high⁴ even when compared with Framingham¹⁹ and the MI incidence rate is low.¹ Lifestyle and the interaction between genes and environmental factors may play a crucial part in determining these differences.²⁰ Physical activity and intake of antioxidants is on average greater in Gerona than in the United States. These habits may counteract the effect of traditional cardiovascular risk factors.⁶ However, while the inclusion of additional risk factors might improve precision, the trade off in terms of additional data acquisition might not be worthwhile.

The risk functions derived from the Framingham experience can be transported to other regions where relative risks are similar, but absolute risks differ from Framingham. Although the estimated to observed ratio was consistently close to 1.0 across all age groups in men, the estimates exceeded 1.0 for women. This difference may be attributed to the low number of cases in younger age groups and the decreasing prevalence of smoking with age observed in women.⁴

The use of CHD prediction functions can be extended to many areas, but each area needs to carefully assess how well the estimates fit the local incidence of CHD. Without this assessment, overestimation might occur and lead to inappropriate treatment for CHD primary prevention. Functions and charts provide an estimate of what happens on average in people with similar cardiovascular risk factors, age, and sex. The correction proposed in this work adds precision to the CHD risk estimations in Spain, but does not indicate the best primary prevention approach in a particular patient. Such a strategy should be decided by taking into account the best evidence from clinical trials.

Characteristics, assumptions, and limitations of the study

In this study we assumed that the Gerona population has the same risk factor distribution as the random sample we studied in 1995. This assumption is acceptable because the participation rate was high in the 1995 study (72%).⁴ Another reasonable assumption was that the population in each age and sex range varied little over the 10 year study period as the variability was, as shown, very low. MI incidence rate was assumed to have remained steady over the past 10 years, which is true according to our own data (see fig 1) and those of other studies.²¹

We assumed the exposure of the Gerona population to risk factors to have been constant over the study period. Cardiovascular risk factor prevalence is not likely to have changed in the past 30 years according to existing surveys and cohort studies.^{4 22 23}

To ensure that our correction did not underestimate the CHD risk, we made all calculations using a conservative approach: cumulated incidence rate (attack rate) was used rather than incidence rate, the <35 years age group was omitted, and our estimates of CHD risk (that is, coronary deaths and non-fatal MI) were for people who had not developed CHD symptoms. The "insufficient data" category was also included in the observed number of events.

Unrecognised Q-wave MI may represent a significant proportion of new CHD events, and Framingham has reported up to 28% of events in men and 35% of events in women.²⁴ Similarly, angina pectoris represented 17% of initial CHD events in men and 27% of events in women.²⁵ As these outcomes were included in the Framingham function⁸ but not in the Gerona registry, we used a specific function, which excluded angina in the end points, developed for this purpose with the Framingham data.

In conclusion, our results support the common impression among physicians that the Framingham function overestimates the risk of coronary events in Mediterranean countries of southern Europe. According to our data, the overestimation may be of an order of magnitude of three in men and two in women aged 35–74. We provide a relatively simple calibration procedure that may be used to estimate individual MI risk with the Framingham function in regions with MI incidence and risk factor prevalence similar to those of Gerona, Spain.

ACKNOWLEDGEMENTS

The authors appreciate the comments of Drs MT Faixedas, JR Banegas, F Rodríguez-Artalejo, and I Rohlf on an earlier version of this manuscript, and wish to thank Joan Vila for statistical analysis and advice, and C O'Hara for English revision of the manuscript.

APPENDIX

Recalibration of the Framingham Functions

To recalibrate the Framingham function to Gerona, we need the population prevalence for the cardiovascular risk factors used in the Framingham function and the average survival (CHD free event rate) for Gerona. Below we illustrate how we obtain the recalibration.

Comparison Between Framingham and Gerona

In table 1 we provide the coefficients of the Framingham functions for men and women. In addition, we display the means of each of the risk factors in the Framingham men and women along with the means of the risk factors in the Gerona men and women. The 10 year event rates for Framingham and Gerona men are shown at the bottom of table 2.

The men in the Gerona sample were older than the Framingham men, they had higher total cholesterol levels, higher HDL cholesterol levels, higher blood pressure, a higher proportion were diabetic, and a slightly higher proportion smoked. The 10 year average event rate was 0.057 in Framingham and 0.035 in Gerona. Below we illustrate how to use the function directly and then how to recalibrate. We do this with specific examples.

Using the Framingham functions directly to estimate risk

The Framingham functions are used as follows to generate estimates of 10 year risk of hard CHD.

$$\text{Ten year risk estimate} = 1 - S(t)^{\exp(\sum \beta_i X_i - \sum \beta_i \bar{X}_i)}$$

where $S(t)$ is the 10 year average rate free of hard CHD (that is, 1–event rate at 10 years = $1 - P(10/X)$),

β_i are the Cox regression coefficients for each level of each risk factor,

X_i are the values of the risk factors for a given patient, and

$\bar{X}_i$ are the means of the risk factors.

We now estimate the 10 year risk for a diabetic, non-smoking man aged 50 with a total cholesterol of 210, HDL of 52, and high normal blood pressure using the Framingham functions directly (that is, using the Framingham means of the risk factors and the Framingham CHD event rate). In the following we break the computation into parts. With the exception of age, which is entered into the computations in years, the remaining risk factor categories are indicated by 1 for the specific category of interest and 0 otherwise. Firstly, we compute the following for this risk factor profile:

$$\sum \beta_i X_i = 0.05(50) + 0.57(1) + 0.00(1) + 0.42(1) + 0.53(1) + 0.73(0) = 4.02$$

Now using the means (in this case the proportions of Framingham men in each risk factor category, except for age in which case we use the mean age) for each of the risk factors:

$$\sum \beta_i \bar{X}_i = 0.05[48.3] - 0.38[0.075] + 0.57[0.390] + 0.74[0.165] + 0.83[0.057]$$

$$+ 0.61[0.192] + 0.37[0.357] - 0.46[0.106] + 0.09[0.202] + 0.42[0.202] + 0.66[0.225]$$

$$+ 0.90[0.128] + 0.53[0.050] + 0.73[0.403] = 3.84.$$

Next,

$$\exp(\Sigma\beta_iX_i - \Sigma\beta_i\bar{X}_i) = \exp(4.02 - 3.84) = 1.20.$$

Then, the average 10 year Framingham probability of not developing hard CHD is 0.943: $S(t=10 \text{ years}) = 1 - 0.057 = 0.943$.

The risk estimate is

$$\text{Ten year risk estimate} = 1 - S(t)^{\exp(\Sigma\beta_iX_i - \Sigma\beta_i\bar{X}_i)} = 1 - 0.943^{1.20} = 0.068$$

Recalibrating the Framingham functions

Now, application of a prediction function computed in one setting to another may not be possible until calibration adjustments for mean levels of risk factors ($\bar{X}_i$) and event rates ($S(10 \text{ years})$) are made. For Cox regression these adjustments are equivalent to replacing the Framingham means of the risk factors ($\bar{X}_1, \dots, \bar{X}_5$) and the Framingham event rate in the Framingham Cox regression models with those of Gerona. $S(t)$ is the Framingham Study's average event rate at time t (we use 10 years) or, more precisely, the probability of not developing CHD at the mean age and values of the risk factors.

Example of recalibration

In the following we again estimate 10 ten year risk for a diabetic, non-smoking man age 50 with a total cholesterol of 210, HDL of 52 and high normal blood pressure using the Framingham functions replacing the Framingham means of the risk factors by those observed in the Gerona study and replacing the Framingham survival rate by that observed in Gerona. Again, we break the computation into parts. Firstly, we compute the following for this risk factor profile (this is, identical to that shown above):

$$\Sigma\beta_iX_i = 0.05(50) + 0.57(1) + 0.00(1) + 0.42(1) + 0.53(1) + 0.73(0) = 4.02$$

Now using the means of the risk factors from Gerona:

$$\begin{aligned} \Sigma\beta_i\bar{X}_i &= 0.05(54.6) - 0.38(0.059) + 0.57(0.348) \\ &+ 0.74(0.281) + 0.83(0.105) \\ &+ 0.61(0.170) + 0.37(0.319) - 0.46(0.175) + 0.09(0.181) \\ &+ 0.42(0.201) + 0.66(0.284) \\ &+ 0.90(0.147) + 0.53(0.093) + 0.73(0.423) = 4.32. \end{aligned}$$

Next,

$$\exp(\Sigma\beta_iX_i - \Sigma\beta_i\bar{X}_i) = \exp(4.02 - 4.32) = 0.741.$$

Then, the average 10 year Gerona probability of not developing hard CHD is 0.965:

$$S(t=10 \text{ years}) = 1 - 0.035 = 0.965.$$

The risk estimate is

$$\text{Ten year risk estimate} = 1 - S(t)^{\exp(\Sigma\beta_iX_i - \Sigma\beta_i\bar{X}_i)} = 1 - 0.965^{0.741} = 0.047$$

Note that the recalibrated 10 year risk estimate is approximately two thirds that produced by the Framingham function without recalibration.

.....

Authors' affiliations

J Marrugat, R Elosua, R Ramos, Unitat de Lipids i Epidemiologia Cardiovascular, Institut Municipal d'Investigació Mèdica (IMIM), Spain
J Marrugat, P Solanas, Universitat Autònoma de Barcelona, Spain
R D'Agostino, W B Kannel, L Sullivan, P Wilson, Framingham Heart Study and Boston University, Boston, USA
J Ordovás, TUFTS University, Boston, USA
J Sala, R Masiá, Servei de Cardiologia i Unitat Coronària, Hospital de Girona Josep Trueta, Girona, Spain
P Solanas, F Cordon, Àrea Bàsica de Salut Girona-3 and Unitat Docent de Medicina de Família de Girona, Spain

Funding: this project was supported by grant 99/226 from Commission for Cultural, Educational and Scientific Exchange between the United States of America and Spain, by grants FIS 93/0568, FIS 96/0026-01

and 94/0539 from the Fondo de Investigación Sanitaria and received partial support through grant CIRIT/1999 SGR 00234 of the Generalitat de Catalunya. R Elosua was supported by an award of Fulbright Program and Generalitat de Catalunya.

Conflicts of interest: none declared.

REFERENCES

- Pérez G, Pena A, Sala J, et al, and the REGICOR Investigators. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in Gerona, Spain, 1990-1992. *Int J Epidemiol* 1998;**27**:599-604.
- Artaud-Wild SM, Connor SL, Sexton G, et al. Differences in coronary mortality can be explained by differences in cholesterol and saturated fat intakes in 40 countries but not in France and Finland. *Circulation* 1993;**88**:2771-9.
- Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, et al. WHO MONICA Project. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. *Circulation* 1994;**90**:583-612.
- Masiá R, Pena A, Marrugat J, et al, and the REGICOR Investigators. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence. *J Epidemiol Community Health* 1998;**52**:707-15.
- Martínez de Aragón MV, Llacer A. Mortalidad en España 1995. *Boletín Epidemiológico Semanal* 1998;**6**:105-16.
- Marrugat J, Masiá R, Elosua R, et al. Cardiovascular protective factors: can they explain the differences in mortality and morbidity between the Mediterranean and the Anglo-Saxon population? *Cardiovascular Risk Factors* 1998;**8**:196-204.
- Marrugat J, Sentí M. Why mortality from heart disease is low in France. High cholesterol may not have the same effect on cardiovascular risk in southern Europe as elsewhere. [Letter]. *BMJ* 2000;**320**:7229.
- Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. *Circulation* 1998;**97**:1837-47.
- Kannel WB, Larson M. Long-term epidemiologic prediction of coronary disease. *Cardiology* 1993;**82**:137-52.
- Wallis EJ, Ramsay LE, Haq IU, et al. Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population. *BMJ* 2000;**320**:671-6.
- Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the Seven Countries Study. *JAMA* 1995;**274**:131-6.
- van den Hoogen PC, Feskens EJ, Nagelkerke NJ, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. *N Engl J Med* 2000;**342**:1-8.
- D'Agostino RB, Grundy S, Sullivan LM, et al. Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation. *JAMA* 2001;**286**:180-7.
- Grundy SM, Balady GJ, Criqui MH, et al. Primary prevention of coronary disease: guidance from Framingham. A statement for healthcare professionals from the AHA Task Force on Risk Reduction. *Circulation* 1998;**97**:1876-87.
- Haq IU, Jackson PR, Yeo WW, et al. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. *Lancet* 1995;**346**:1467-71.
- Ramsay LE, Haq IU, Jackson PR, et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. *Lancet* 1996;**348**:387-8.
- Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction chart. *BMJ* 2000;**320**:709-10.
- Menotti A, Puudu PE, Lantti M. Comparison of the Framingham risk function-based coronary chart risk function from an Italian population study. *Eur Heart J* 2000;**21**:365-70.
- Ordovas JM. Colesterol y tabaco: clásicos que perduran en el tiempo. *Rev Esp Cardiol* 2001;**54**:1143-5.
- Sentí M, Ordovas JM. Understanding the effects of protective interactions between genetic and environmental factors on cardiovascular ischaemic diseases. *Cardiovascular Risk Factors* 1998;**8**:90-7.
- Anonymous. Tendències de la malaltia coronària a Catalunya, 1985-97: projecte MONICA. *Butlletí Epidemiològic de Catalunya* 2000;**XXI**:1-6.
- Dobson AJ, Evans A, Ferrario M, et al. Changes in estimated coronary risk in the 1980s: data from 38 populations in the WHO MONICA Project. World Health Organization. Monitoring trends and determinants in cardiovascular diseases. *Ann Med* 1998;**30**:199-205.
- Tomas-Abadal L, Varas-Lorenzo C, Bernades-Bernat E, et al. Coronary risk factors and a 20-year incidence of coronary heart disease and mortality in a Mediterranean industrial population. The Manresa Study, Spain. *Eur Heart J* 1994;**15**:1028-36.
- Kannel WB. Silent myocardial ischemia and infarction: insights from the Framingham Study. *Cardiol Clin* 1986;**4**:583-91.
- Sykowski PA, D'Agostino RB, Belanger A, et al. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study 1950-1989. *Am J Epidemiol* 1996;**143**:338-50.